MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

On location

Evaluating PRM-151 in Patients With Myelofibrosis Resistant or Intolerant to Ruxolitinib

According to results from a double-blind, phase II study, PRM-151 improved bone marrow fibrosis severity, transfusion dependence, and other symptoms in a cohort of...
On location

Exploring Safety and Efficacy of 5F9 and Azacitidine in AML and MDS

In initial results from a phase Ib trial presented at the 2019 American Society of Clinical Oncology annual meeting, the CD47-targeting antibody Hu5F9-G4 (5F9)...

Naveen Pemmaraju: A New Option for Myelofibrosis?

Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
David Sallman, MD

David Sallman: Early Results of 5F9 in AML and MDS

David Sallman, MD, discusses the initial results seen in a phase Ib trial of the anti-CD47 antibody 5F9 in patients with acute myeloid leukemia...

Five Decades of Experience With MPNs: Characterizing Survival and Outcomes

A report based on data from more than 3,000 patients with myeloproliferative neoplasms (MPNs) evaluated at the Mayo Clinic in Rochester, Minnesota, over 50...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including the first treatment...
On location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...

CHIP-Associated Mutations Linked With Comorbidities in MDS

The presence of clonal hematopoiesis of indeterminate potential (CHIP) mutations, particularly DNMT3A and JAK2 mutations, was associated with a higher likelihood of prior myocardial...
On location

A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?

A study of patients with bone marrow failure (BMF) and short telomeres found that a conditioning regimen that eliminates radiation and DNA-alkylating agents led...
You Make the Call

The significance of JAK2-positive test results in a healthy patient

This month Josef Prchal, MD, discusses the significance of JAK2-positive test results in a healthy patient. And don't forget to check out next month's clinical dilemma...

SHARE